Socially optimal pandemic drug dosing.

Strohbehn, Garth W; Parker, William F; Reid, Pankti D; Gellad, Walid F

Strohbehn, Garth W; Parker, William F; Reid, Pankti D; Gellad, Walid F.

Strohbehn GW; Center for Clinical Management and Research, Veterans Affairs Ann Arbor Medical Center, Ann Arbor, MI 48105, USA; Rogel Comprehensive Cancer Center, University of Michigan Medicine, Ann Arbor, MI, USA. Electronic address: gstrohbe@umich.edu.
Parker WF; Section of Pulmonary/Critical Care Medicine, University of Chicago Medicine, Chicago, IL, USA; MacLean Center for Clinical Medical Ethics, University of Chicago, Chicago, IL, USA.
Reid PD; Section of Rheumatology, University of Chicago Medicine, Chicago, IL, USA; Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago Medicine, Chicago, IL, USA.
Gellad WF; Center for Pharmaceutical Policy and Prescribing, Center for Health Equity and Research Promotion, and Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Lancet Glob Health ; 9(8): e1049-e1050, 2021 08.

Article in English | MEDLINE | ID: covidwho-1267387

Subject(s)

COVID-19; Pharmaceutical Preparations/administration & dosage; Randomized Controlled Trials as Topic; Humans; Pharmaceutical Preparations/supply & distribution; United Kingdom/epidemiology

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pharmaceutical Preparations / Randomized Controlled Trials as Topic / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Lancet Glob Health Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google